COVID & other Diseases

COVID & other Diseases

303 bookmarks
Custom sorting
COVID-19 studies -Infectious Diseases
COVID-19 studies -Infectious Diseases
Explore the latest in infectious diseases, including community-acquired and nosocomial disease, antibiotic use and stewardship, and more.
·jamanetwork.com·
COVID-19 studies -Infectious Diseases
Spraying disinfectants can be 'harmful', says WHO
Spraying disinfectants can be 'harmful', says WHO
Spraying disinfectant on the streets, as practised in some countries, does not eliminate the novel coronavirus and even poses a health risk, the World Health Organization (WHO) warned on Saturday.In a
·thehindu.com·
Spraying disinfectants can be 'harmful', says WHO
[Theoretical, methodological and practical problems of virus disinfection in human medicine (author's transl)]. - PubMed - NCBI
[Theoretical, methodological and practical problems of virus disinfection in human medicine (author's transl)]. - PubMed - NCBI
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
·ncbi.nlm.nih.gov·
[Theoretical, methodological and practical problems of virus disinfection in human medicine (author's transl)]. - PubMed - NCBI
Bid to reduce respiratory COVID-19 deaths – News
Bid to reduce respiratory COVID-19 deaths – News
Acute Respiratory Distress Syndrome in patients with COVID-19 can lead to death but more than 50% of these cases are associated with co-infection with bacterial pathogens. …
·news.flinders.edu.au·
Bid to reduce respiratory COVID-19 deaths – News
'No Evidence' Yet That Recovered COVID-19 Patients Are Immune, WHO Says
'No Evidence' Yet That Recovered COVID-19 Patients Are Immune, WHO Says
The World Health Organization warned against "immunity passports," which allow travel only to recovered patients, saying studies must first confirm whether people are indeed safe from reinfection.
·npr.org·
'No Evidence' Yet That Recovered COVID-19 Patients Are Immune, WHO Says
COVID-19/SARS-CoV-2
COVID-19/SARS-CoV-2
PubChem trial studies
·pubchemdocs.ncbi.nlm.nih.gov·
COVID-19/SARS-CoV-2
Case for continuing community NIV and CPAP during the COVID-19 epidemic
Case for continuing community NIV and CPAP during the COVID-19 epidemic
Dear Editor, Recent clinical guidelines regarding the use of home non-invasive ventilation (NIV) and continuous positive airway pressure (CPAP) during the COVID-19 epidemic have tried to balance the risks of stopping NIV or CPAP against the unknown potential risk of increased aerosol-related transmission to family and carers.1 2 We read with interest views put forward by Barker et al 3 but feel that wider aspects need consideration, and for NIV and CPAP separately. NIV use: NIV is primarily used for those with previous, or at risk from, hypercapnic respiratory failure (neuromuscular disorde...
·thorax.bmj.com·
Case for continuing community NIV and CPAP during the COVID-19 epidemic
Coronavirus pandemic: Updates from around the world - CNN
Coronavirus pandemic: Updates from around the world - CNN
The global coronavirus pandemic has brought countries around the world to a standstill. Here's the latest updates on worldwide Covid-19 cases, deaths, government responses, and more.
·cnn.com·
Coronavirus pandemic: Updates from around the world - CNN
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus.
·mmrjournal.biomedcentral.com·
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status